Role of everolimus in pancreatic neuroendocrine tumors (Q37935772)

25 August 2017

1 reference

title

Role of everolimus in pancreatic neuroendocrine tumors (English)

1 reference

25 August 2017

Robert Goldstein

1

1 reference

25 August 2017

Tim Meyer

series ordinal

2

1 reference

25 August 2017

publication date

20 September 2011

1 reference

Expert Review of Anticancer Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1653-1665

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Neuroendocrine tumor epidemiology: contrasting Norway and North America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Tumour biology and histopathology of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Positional cloning of the gene for multiple endocrine neoplasia-type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

A simplified prognostic system for resected pancreatic neuroendocrine neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Pharmacokinetic interaction between verapamil and everolimus in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.145

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.1586/ERA.11.145

1 reference

25 August 2017

1 reference